Healthcare
PeptiDream Inc.(PPTDF)
Live Price
Offline$6.00
+0.00% today
Window Change
-17.92%
Window
May 29, 2026 โ Jun 15, 2026
- Market Cap
- $150.79B
- Revenue Growth
- -60.3%
- EPS Growth
- -125.7%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 12 bars ยท May 29, 2026 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PeptiDream Inc. (PPTDF) is a Healthcare stock with a market cap of $150.79B and listed on OTC. The stock last traded around $6.00 and down 17.9% across the available one-year price window (May 29, 2026 โ Jun 15, 2026). Baseline metrics include revenue growth of -60.3%, EPS growth of -125.7%, a dividend yield of 0.0%. What stands out right now is revenue -60.3%, EPS -125.7%, free cash flow -169.0% with operating margin -26.9% and ROIC -5.0%. Valuation already assumes a fairly strong business story at price/sales 8.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PPTDF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-60.3% vs +7.6% peer median
Operating Margin
Below sector median
-26.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 7, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -60.3% and EPS is at -125.7%, with operating margin around -26.9%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PPTDF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PPTDF Max Drawdown
-18.19%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PPTDF and SPY.
Company Overview
PeptiDream Inc.
Other OTC
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
- Leadership
- Patrick Crawford Reid
- IPO Date
- Aug 20, 2014
- Employees
- 621
- Street Address
- 3-25-23 Tonomachi
- Mailing
- Kawasaki, 210-0821
- Region
- Kawasaki, JP
- Reporting Currency
- USD
- Investor Line
- 81 4 4270 1300
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.1
- Price/Book
- 2.9
Growth
- Revenue
- -60.3%
- EPS
- -125.7%
- Free Cash Flow
- -169.0%
Profitability
- Gross Margin
- 40.6%
- Operating Margin
- -26.9%
- Net Margin
- -20.2%
- ROE
- -7.1%
- ROIC
- -5.0%
Balance Sheet
- Debt/Equity
- 0.33
- Current Ratio
- 1.66
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.